GPT and metabolic dysfunction-associated steatohepatitis: In addition, NASH-induced increases in serum parameters indicating liver damage, including FFAs, AST, and ALT, were more significantly inhibited by KY19334 treatment than by selonsertib or ocaliva treatment (Fig. 6k).